3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
15
Neoplasms
10
Carcinoma, Renal Cell
8
Carcinoma, Hepatocellular
8
Melanoma
7
Carcinoma, Non-Small-Cell Lung
7
Endometrial Neoplasms
6
Thyroid Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
Recurrence
4
Thyroid Cancer, Papillary
3
Stomach Neoplasms
3
Neuroendocrine Tumors
3
Colorectal Neoplasms
3
Adenocarcinoma, Follicular
3
Ovarian Neoplasms
2
Osteosarcoma
2
Neoplasm Metastasis
2
Lymphoma
2
Lung Neoplasms
2
Glioma
2
Carcinoma, Transitional Cell
2
Carcinoma
2
Biliary Tract Neoplasms
2
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Thyroid cancer, medullary
1
Thyroid cancer, Hurthle cell
1
Thyroid Diseases
1
Thyroid Carcinoma, Anaplastic
1
Interventions
pembrolizumab
37
Paclitaxel
36
Carboplatin
31
Cyclophosphamide
22
Albumin-Bound Paclitaxel
20
atezolizumab
16
130-nm albumin-bound paclitaxel
16
Taxes
15
Doxorubicin
15
Cisplatin
13
Capecitabine
13
Nivolumab
10
Docetaxel
8
olaparib
7
Gemcitabine
6
Everolimus
6
talazoparib
5
durvalumab
5
Magnetic Resonance Spectroscopy
5
Biopsy
5
Bevacizumab
5
veliparib
4
spartalizumab
4
sacituzumab govitecan
4
pegfilgrastim
4
liposomal doxorubicin
4
eribulin
4
Specimen Handling
4
Immunoglobulin G
4
trilaciclib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Triple Negative Breast Neoplasms
×
lenvatinib
×
Clear all
NCT03797326
2026-05-04
LEAP-005
Merck Sharp & Dohme LLC
Phase 2
Completed
611 enrolled
27 charts